| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fucoidan is found in brown algae. Extracted from the seaweed species Fucus vesiculosus, Cladosiphon okamuranus, Laminaria japonica and Undaria pinnatifida. In oncology research, fucoidan is most consistently described as an immunomodulatory and anti-angiogenic compound with additional pro-apoptotic and anti-metastatic effects in preclinical models. Mechanistically, fucoidan has been reported to suppress NF-κB and PI3K/AKT signaling, reduce VEGF-mediated angiogenesis, inhibit tumor cell adhesion and invasion, and promote apoptosis through caspase activation and mitochondrial pathways. It may also enhance NK cell and macrophage activity, contributing to anti-tumor immune responses. Effects vary substantially depending on molecular weight, sulfation pattern, and source species. Human clinical data remain limited, and many anticancer claims are derived from in vitro and animal studies. Fucoidan — a heterogeneous family of fucose-rich, sulfated polysaccharides obtained primarily from the cell walls of brown algae. It is classified as a marine-derived polysaccharide nutraceutical and experimental biologic rather than a single chemically defined drug. Standard abbreviations include FUC, FD, LMF or LMWF for low-molecular-weight fucoidan, and OF or oligo-fucoidan for depolymerized preparations. Major sources include Fucus vesiculosus, Undaria pinnatifida, Cladosiphon okamuranus, Saccharina japonica, and related brown seaweeds. Molecular weight, branching, sulfate content, monosaccharide composition, contaminants, and extraction method differ substantially among products and strongly affect biological activity. Primary mechanisms (ranked):
Bioavailability / PK relevance: Intact high-molecular-weight fucoidan has limited and variable gastrointestinal absorption. Small quantities of orally administered fucoidan or fucoidan-derived fractions can be detected in human serum and urine, but systemic exposure is low, assay-dependent, and influenced by molecular weight, sulfation, source species, microbiota, and formulation. Low-molecular-weight and oligosaccharide preparations generally have greater absorption and tissue accessibility than native polymers. Local intestinal, microbiome-mediated, endothelial, and immune effects may therefore be more pharmacologically relevant than direct exposure of distant tumors after ordinary oral supplementation. In-vitro vs systemic exposure relevance: Many direct anticancer experiments use approximately 50–1000 µg/mL fucoidan, concentrations that are unlikely to be reproduced as freely circulating intact polysaccharide after conventional oral dosing. Direct tumor-cell apoptosis and kinase inhibition demonstrated at these levels should therefore be considered high-concentration or formulation-dependent findings. Lower-concentration receptor, endothelial, coagulation, intestinal, and immune effects may be more clinically plausible. Nanoparticle, injectable, radiolabelled, and chemically depolymerized fucoidan preparations are not pharmacokinetically interchangeable with oral seaweed extracts. Clinical evidence status: Predominantly preclinical, with several small human studies and randomized adjunct trials. Small colorectal and rectal cancer studies have reported possible improvements in disease control, treatment tolerance, quality of life, or selected inflammatory outcomes, and a 2025 randomized trial reported improved outcomes when low-molecular-weight fucoidan was added to transarterial chemoembolization for unresectable hepatocellular carcinoma. However, studies remain heterogeneous, generally small, formulation-specific, and insufficient to establish fucoidan as an anticancer treatment. Additional randomized phase II studies are registered for cancer-related fatigue, cachexia, chemoradiotherapy, and other supportive indications. Fucoidan is not an approved anticancer drug and no oncology guideline currently recommends routine therapeutic use. Safety and interaction constraints: Oral preparations have generally been well tolerated in small studies, but safety cannot be generalized across poorly standardized extracts. Fucoidan can exhibit anticoagulant, antiplatelet, or fibrinolytic activity depending on molecular weight and sulfation; caution is appropriate with warfarin, heparins, direct oral anticoagulants, antiplatelet drugs, bleeding disorders, or perioperative use. Seaweed-derived products may also contain variable iodine, sodium, heavy metals, or other polysaccharides. Potential interactions with chemotherapy, immunotherapy, and drug absorption remain incompletely characterized. Fucoidan Mechanistic Profile
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Hypoxia-Inducible-Factor 1A (HIF1A gene, HIF1α, HIF-1α protein product) -Dominantly expressed under hypoxia(low oxygen levels) in solid tumor cells -HIF1A induces the expression of vascular endothelial growth factor (VEGF) -High HIF-1α expression is associated with Poor prognosis -Low HIF-1α expression is associated with Better prognosis -Functionally, HIF-1α is reported to regulate glycolysis, whilst HIF-2α regulates genes associated with lipoprotein metabolism. -Cancer cells produce HIF in response to hypoxia in order to generate more VEGF that promote angiogenesis Key mediators of aerobic glycolysis regulated by HIF-1α. -GLUT-1 → regulation of the flux of glucose into cells. -HK2 → catalysis of the first step of glucose metabolism. -PKM2 → regulation of rate-limiting step of glycolysis. -Phosphorylation of PDH complex by PDK → blockage of OXPHOS and promotion of aerobic glycolysis. -LDH (LDHA): Rapid ATP production, conversion of pyruvate to lactate; HIF-1α Inhibitors: -Curcumin: disruption of signaling pathways that stabilize HIF-1α (ie downregulate). -Resveratrol: downregulate HIF-1α protein accumulation under hypoxic conditions. -EGCG: modulation of upstream signaling pathways, leading to decreased HIF-1α activity. -Emodin: reduce HIF-1α expression. (under hypoxia). -Apigenin: inhibit HIF-1α accumulation. |
| 948- | Fuc, | Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia |
| - | vitro+vivo, | Bladder, | T24/HTB-9 | - | in-vitro, | Nor, | HUVECs |
| 7008- | Fuc, | Ten Years of Research on Fucoidan and Cancer: Focus on Its Antiangiogenic and Antimetastatic Effects |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:81 Target#:143 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid